Синдром раздраженного кишечника и микробиота: пути оптимизации терапии
- Авторы: Осадчук М.А1, Осадчук М.М2
-
Учреждения:
- Первый МГМУ им. И.М. Сеченова
- Городская поликлиника № 52 Департамента здравоохранения Москвы
- Выпуск: Том 26, № 5 (2015)
- Страницы: 47-51
- Раздел: Статьи
- URL: https://journals.eco-vector.com/0236-3054/article/view/116295
- ID: 116295
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Представлен аналитический обзор, посвященный роли микрофлоры кишечника в формировании синдрома раздраженного кишечника (СРК). Не вызывает сомнения то, что микрофлора кишечника может инициировать симптомы СРК, изменяя нейромоторные сенсорные, барьерные функции кишечника и их взаимодействие по оси мозг-кишечник.
Ключевые слова
Полный текст
Об авторах
М. А Осадчук
Первый МГМУ им. И.М. Сеченова
Email: osadchuk.mikhail@yandex.ru
доктор медицинских наук, профессор
М. М Осадчук
Городская поликлиника № 52 Департамента здравоохранения Москвыкандидат медицинских наук
Список литературы
- Захаренко С.М. Антибиотики и пробиотики: конкуренты или синергисты? // Эпидем. и инфекцион. бол. - 2007; 5 (1): 47-53.
- Осадчук М.А., Свистунов А.А. Антибиотикоассоциированная диарея в клиничес-кой практике // Вопр. соврем. педиатрии. - 2014; 13 (1); 102-8.
- Парфенов А.И., Ручкина И.Н., Атауллаханов Р.И. Постинфекционный синдром раздраженного кишечника. Особенности патогенеза, диагностики и лечения // Рус. мед. журн. - 2009; 11 (2): 1-5.
- Amaral F., Sachs D., Costa V. et al. Commensal microbiota is fundamental for the development of inflammatory pain // Proc. Natl. Acad. Sci. USA. - 2008; 105: 2193-7.
- Asano Y., Hiramoto T., Nishino R. et al. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice // Am. J. Physiol. Gastrointest. Liver Physiol. - 2012; 303: 1288-95.
- Lyte M. Microbial endocrinology and infectious disease in the 21st century // Trends Microbiol. - 2004; 12: 14-20.
- Belmonte L., Beutheu-Youmba S., Bertiaux-Vandaële N. et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype // PLoS One. - 2012; 7: 42777.
- Bindels L., Dewulf E., Delzenne N. GPR43/FFA2: physiopathological relevance and therapeutic prospects // Trends Pharmacol. Sci. - 2013; 34: 226-32.
- Bouhnik Y., Alain S., Attar A. et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome // Am. J. Gastroenterol. - 1999; 94: 1327-31.
- Buhner S., Li Q., Vignali S. et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome // Gastroenterology. - 2009; 137: 1425-34.
- Carroll I., Ringel-Kulka T., Siddle J. et al. Characterization of the fecal microbiota using high-throughput sequencing reveals a stable microbial community during storage // PLoS One. - 2012; 7: 46953.
- Chalmers N., Palmer R., Cisar J. et al. Characterization of a Streptococcus spр. - Veillonella spр. community micromanipulated from dental plaque // J. Bacteriol. - 2008; 190: 8145-54.
- Cogan T., Thomas A., Rees L. et al. Norepinephrine increases the pathogenic potential of Campylobacter jejuni // Gut. - 2007; 56: 1060-5.
- Faith J., Guruge J., Charbonneau M. et al. The long-term stability of the human gut microbiota // Science. - 2013; 341: 1237439.
- Fukudo S. Pathogenesis of irritable bowel syndrome // Nihon Shokakibyo Gakkai Zasshi. - 2014; 111 (7): 1323-33
- Guglielmetti S., Mora D., Gschwender M. et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study // Aliment. Pharmacol. Ther. - 2011; 33: 1123-32.
- Ivanov D., Emonet C., Foata F. et al. A serpin from the gut bacterium Bifidobacteriumlongum inhibits eukaryotic elastase-like serine proteases // J. Biol. Chem. - 2006; 281: 17246-52.
- Jeffery I., O’Toole P., O’hman L. et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota // Gut. - 2012; 61: 997-1006.
- Lekha Saha. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine // World J. Gastroenterol. - 2014; 20 (22): 6759-73.
- Liebregts T., Adam B., Bredack C. et al. Immune activation in patients with irritable bowel syndrome. Immune activation in patients with irritable bowel syndrome // Gastroenterology. - 2007; 132: 913-20.
- Lyra A., Rinttilä T., Nikkilä J. et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification // World J. Gastroenterol. - 2009; 15: 5936-45.
- Lyte M. Microbial endocrinology and infectious disease in the 21st century // Trends Microbiol. - 2004; 12: 14-20.
- Lyte M., Freestone P. Microbial Endocrinology: interkingdom signaling in health and disease. Springer Publishers; 2010.
- Macfarlane G., Allison C., Gibson S. et al. Contribution of the microflora to proteolysis in the human large intestine // J. Appl. Bacteriol. - 1988; 64: 37-46.
- Macfarlane S., Woodmansey E., Macfarlane G. Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system // Appl. Environ. Microbiol. - 2005; 71: 7483-92.
- Malinen E., Rinttilä T., Kajander K. et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR // Am. J. Gastroenterol. - 2005; 100: 373-82.
- Matricon J., Meleine M., Gelot A. et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome // Aliment. Pharmacol. Ther. - 2012; 36: 1009-31.
- Milani C., Hevia A., Foroni E. et al. Assessing the fecal microbiota: an optimized ion torrent 16S rRNA gene-based analysis protocol // PLoS One. - 2013; 8 (7): 68739
- Nam Y., Jung M., Roh S. et al. Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing // PLoS One. - 2011; 6: 22109.
- Nohr M., Pedersen M., Gille A. et al. GPR41/FFAR3 and GPR43/FFAR2 as Cosensors for Short-Chain Fatty Acids in Enteroendocrine Cells vs FFAR3 in Enteric Neurons and FFAR2 in Enteric Leukocytes // Endocrinology. - 2013; 154: 3552
- Paliy O., Kenche H., Abernathy F. et al. High-throughput quantitative analysis of the human intestinal microbiota with a phylogenetic microarray // Appl. Environ. Microbiol. - 2009; 75: 3572-9.
- Parkes G., Sanderson J., Whelan K. Treating irritable bowel syndrome with probiotics: the evidence // Proc. Nutr. Soc. - 2010; 69: 187-94.
- Parkes G., Rayment N., Hudspith B. et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome // Neurogastroenterol. Motil. - 2012; 24: 31-9.
- Qin J., Li R., Raes J. et al. A human gut microbial gene catalogue established by metagenomic sequencing // Nature. - 2010; 464: 59-65.
- Quigley E., Craig O. Irritable bowel syndrome; update on pathophysiology and management // Turk. J. Gastroenterol. - 2012; 23 (4): 313-22.
- Rajilic-Stojanovic M., Biagi E., Heilig H. et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome // Gastroenterology. - 2011; 141: 1792-801.
- Rajilic-Stojanovic M. Diversity of the Human Gastrointestinal Microbiota-Novel Perspectives from High Throughput Analyses [PhD thesis] / Wageningen: Wageningen University, 2007.
- Rigsbee L., Agans R., Shankar V. et al. Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome // Am. J. Gastroenterol. - 2012; 107 (11): 1740-51.
- Sanders M., Guarner F., Guerrant R. et al. An update on the use and investigation of probiotics in health and disease // Gut. - 2013; 62: 787-96.
- Santos J., Saperas E., Nogueiras C. et al. Release of mast cell mediators into the jejunum by cold pain stress in humans // Gastroenterology. - 1998; 114: 640-8.
- Simrén M., Barbara G., Flint H. et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report // Gut. - 2013; 62 (1): 159-76.
- Sommer F., Bäckhed F. The gut microbiota--masters of host development and physiology // Nat. Rev. Microbiol. - 2013; 11: 227-38.
- Spiegel B. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective // Clin. Gastroenterol. Hepatol. - 2011; 9: 461-9.
- Spiller R., Garsed K. Postinfectious irritable bowel syndrome // Gastroenterology. - 2009; 136: 1979-88.
- Tana C., Umesaki Y., Imaoka A. et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome // Neurogastroenterol. Motil. - 2010; 22: 512-9, e114-5.
- Thompson W., Longstreth G., Drossman D. et al. Functional bowel disorders and functional abdominal pain // Gut. - 1999; 45 (Suppl. 2): 43-7.
- Saulnier D., Riehle K., Mistretta T. et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome // Gastroenterology. -2011; 141: 1782-91.
- Wilson S., Roberts L., Roalfe A. et al. Prevalence of irritable bowel syndrome: a community survey // Br. J. Gen. Pract. - 2004; 54: 495-502.
- Yang H., Stephens R., Tache Y. TRH analogue microinjected into specific medullary nuclei stimulates gastric serotonin secretion in rats // Am. J. Physiol. -1992; 262(2 Pt 1): 216-22.
- Сухорукова М.В., Тимохова А.В., Эйдельштейн М.В. и др. Чувствительность к антибиотикам штаммов бактерий, входящих в состав пробиотика Линекс® // Клин. микробиол. и антимикроб. химиотер. - 2012; 14 (3): 248-51.